-
Mashup Score: 0GoTo Webinar - 1 year(s) agoSource: register.gotowebinar.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 0
Cochrane Clinical Answers Clinical Answer: For unvaccinated, nonâhospitalized people with symptomatic COVIDâ19 at high risk of progression to severe COVIDâ19, lowâcertainty evidence suggests that fewer people may die and experience worsened clinical status at day 28 with nirmatrelvir/ritonavir compared with placebo (11 and 53 fewer people per 1000, respectively; all results on average)….
Source: www.cochranelibrary.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0What are the benefits and harms of fluvoxamine for adults with mild COVIDâ19? - Ciapponi, AgustĂn - 2022 | Cochrane Library - 2 year(s) ago
Cochrane Clinical Answers Clinical Answer: Lowâcertainty evidence suggests that for adults with mild COVIDâ19, fluvoxamine may slightly reduce allâcause mortality at day 28 (23 vs 33 per 1000 people, all results on average) and may reduce admission to hospital or death (a composite outcome; 73 vs 131 per 1000 people) when compared with placebo. However, the 95% confidence interval is compatible…
Source: www.cochranelibrary.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 3
Cochrane Clinical Answers Clinical Answer: Reviewers performed a rapid scoping review to identify and describe evidence on interventions to increase the COVIDâ19 vaccine uptake and decrease COVIDâ19 vaccine hesitancy. Reviewers identified 61 published studies and 35 ongoing studies, mostly involving a general adult population from highâincome countries. The studies evaluated communication…
Source: www.cochranelibrary.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 2
Cochrane Clinical Answers Clinical Answer: Reviewers performed a rapid scoping review to identify and describe evidence on interventions to increase the COVIDâ19 vaccine uptake and decrease COVIDâ19 vaccine hesitancy. Reviewers identified 61 published studies and 35 ongoing studies, mostly involving a general adult population from highâincome countries. The studies evaluated communication…
Source: www.cochranelibrary.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0What are the effects of janus kinase (JAK) inhibitors for people with moderate to severe COVIDâ19? - Tort, Sera - 2022 | Cochrane Library - 2 year(s) ago
Cochrane Clinical Answers Clinical Answer: For people with moderate to severe COVIDâ19, moderateâ to highâcertainty evidence shows that the addition of JAK inhibitors to standard care leads to lower mortality at day 28 (98 vs 136 per 1000 people; all results on average) and day 60 (106 vs 152 per 1000 people), respectively. Moderateâcertainty evidence shows that compared with standard care…
Source: www.cochranelibrary.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 6
Cochrane Clinical Answers Clinical Answer: Reviewers performed a rapid scoping review to identify and describe the evidence available on unintended health and societal consequences of measures implemented in the school setting to contain the COVIDâ19 pandemic. Reviewers identified 18 studies (13 of which used quantitative methods) and described four intervention categories:…
Source: www.cochranelibrary.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 2Cochrane Clinical Answers related to COVID-19 - 2 year(s) ago
Readable, clinically-focused, actionable answers to inform point-of-care decision-making for health professionals.
Source: www.cochrane.orgCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0What is the accuracy of chest computed tomography (CT) and chest Xâray for the diagnosis of COVIDâ19? - Tort, Sera - 2022 | Cochrane Library - 2 year(s) ago
Cochrane Clinical Answers Clinical Answer: For diagnosing COVIDâ19 using reverse transcriptase polymerase chain reaction (RTâPCR) as the reference standard, chest CT had sensitivities ranging from 45% to 100% and specificities ranging from 10% to 99% across 69 studies with 28,285 participants with suspected COVIDâ19 (14,342 cases). Pooled estimates were 87% for sensitivity…
Source: www.cochranelibrary.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
Cochrane Clinical Answers Clinical Answer: The reviewers wanted to compare a testâbased attendance strategy with a standard 10âday selfâisolation after contact with a SARSâCoVâ2âpositive person, but they identified only very lowâcertainty evidence on rates of SARSâCoVâ2 infection (symptomatic polymerase chain reaction (PCR) positive or any positive PCR). Lowâcertainty…
Source: www.cochranelibrary.comCategories: General Medicine News, Latest HeadlinesTweet
Join us tomorrow for the next episode of The Case and learn more about applying clinical evidence in your daily practice. đ April 27 at 10:00am EDT / 3:00pm BST. Register now: https://t.co/9QW5sIcIE7 #EvidenceBasedMedicine #CochraneClinicalAnswers @CochraneLibrary https://t.co/qlC7MmM7My